Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis
Lu W, Li S, Li J, Wang J, Zhang R, Zhou Y, Yin Q, Zheng Y, Wang F, Xia Y, Chen K, Liu T, Lu J, Zhou Y, Guo C, Guo C
Gastroenterology research and practice · 85 citations
How it was studied
- Design
- Meta-analysis (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
Based on full-text disclosure statement.
Publication
- Published
- 2016-01-01 · Gastroenterol Res Pract · vol. 2016 · pp. 1–11
- Publisher
- Hindawi Publishing Corporation
- Cited
- 132 citations · more than 84% of similar papers · 1.8× the field average
- References
- 48 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Liver Disease Diagnosis and Treatment · Liver Disease and Transplantation · Liver Diseases and Immunity
- Keywords
- Nonalcoholic fatty liver disease, Medicine, Internal medicine, Meta-analysis, Gastroenterology, Triglyceride, Polyunsaturated fatty acid, Randomized controlled trial, Fatty liver, Cholesterol, Fatty acid, Disease, Biochemistry, Biology
15 authors
From CN
- Wenxia LuTongji University; Shanghai Tenth People's Hospital; Nanjing Medical University
- Sainan LiTongji University; Shanghai Tenth People's Hospital
- Jingjing LiTongji University; Shanghai Tenth People's Hospital
- Jianrong WangTongji University; Shanghai Tenth People's Hospital; Nanjing Medical University
- Rong ZhangTongji University; Shanghai Tenth People's Hospital; Nanjing Medical University
- Yuqing ZhouTongji University; Soochow University; Shanghai Tenth People's Hospital; First Affiliated Hospital of Soochow University
Abstract
A meta-analysis was conducted to assess the effect of omega-3 fatty acid supplementation (n-3 PUFAs) in lowering liver fat, liver enzyme (alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase (GGT) levels), and blood lipids (triglyceride (TG), total cholesterol (TC), high density lipoprotein (HDL), and low density lipoprotein (LDL)) in patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). Methods. MEDLINE/PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, CINAHL, Science Citation Index (ISI Web of Science), Chinese Biomedical Literature Database (CBM), and Chinese National Knowledge Infrastructure (CNKI) were searched for relevant randomized controlled trials on the effects of n-3 polyunsaturated fatty acids (PUFAs) in patients with NAFLD from inception to May 2015. Ten studies were included in this meta-analysis. Results. 577 cases of NAFLD/NASH in ten randomized controlled trials (RCTs) were included. The results of the meta-analysis showed that benefit changes in liver fat favored PUFA treatment, and it was also beneficial for GGT, but it was not significant on ALT, AST, TC, and LDL. Conclusions. In this meta-analysis, omega-3 PUFAs improved liver fat, GGT, TG, and HDL in patients with NAFLD/NASH. Therefore, n-3 PUFAs may be a new treatment option for NAFLD.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.